178 related articles for article (PubMed ID: 17224713)
1. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.
Troost PW; Lahuis BE; Hermans MH; Buitelaar JK; van Engeland H; Scahill L; Minderaa RB; Hoekstra PJ
J Clin Psychopharmacol; 2007 Feb; 27(1):52-7. PubMed ID: 17224713
[TBL] [Abstract][Full Text] [Related]
2. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
[TBL] [Abstract][Full Text] [Related]
3. The effect of the Taq1A variant in the dopamine Dâ‚‚ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.
Roke Y; van Harten PN; Franke B; Galesloot TE; Boot AM; Buitelaar JK
Pharmacogenet Genomics; 2013 Sep; 23(9):487-93. PubMed ID: 23851570
[TBL] [Abstract][Full Text] [Related]
4. Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder.
Duval F; Guillon MS; Mokrani MC; Crocq MA; Garcia Duarte F
Psychoneuroendocrinology; 2008 Feb; 33(2):255-9. PubMed ID: 18053652
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
[TBL] [Abstract][Full Text] [Related]
6. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
[TBL] [Abstract][Full Text] [Related]
7. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
Bork JA; Rogers T; Wedlund PJ; de Leon J
J Clin Psychiatry; 1999 Jul; 60(7):469-76. PubMed ID: 10453802
[TBL] [Abstract][Full Text] [Related]
8. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
Yagihashi T; Mizuno M; Chino B; Sato Y; Sakuma K; Takebayashi T; Takao T; Kosaki K
Hum Psychopharmacol; 2009 Jun; 24(4):301-8. PubMed ID: 19387994
[TBL] [Abstract][Full Text] [Related]
9. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.
Anderson GM; Scahill L; McCracken JT; McDougle CJ; Aman MG; Tierney E; Arnold LE; Martin A; Katsovich L; Posey DJ; Shah B; Vitiello B
Biol Psychiatry; 2007 Feb; 61(4):545-50. PubMed ID: 16730335
[TBL] [Abstract][Full Text] [Related]
10. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.
Melkersson KI
Hum Psychopharmacol; 2006 Dec; 21(8):529-32. PubMed ID: 17094165
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone.
Hendset M; Molden E; Refsum H; Hermann M
J Clin Psychopharmacol; 2009 Dec; 29(6):537-41. PubMed ID: 19910717
[TBL] [Abstract][Full Text] [Related]
12. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment.
Masi G; Cosenza A; Mucci M
J Child Adolesc Psychopharmacol; 2001; 11(4):389-94. PubMed ID: 11838821
[TBL] [Abstract][Full Text] [Related]
13. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition.
Nakagami T; Yasui-Furukori N; Saito M; Tateishi T; Kaneo S
Clin Pharmacol Ther; 2005 Jul; 78(1):43-51. PubMed ID: 16003291
[TBL] [Abstract][Full Text] [Related]
14. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes.
Ono S; Mihara K; Suzuki A; Kondo T; Yasui-Furukori N; Furukori H; de Vries R; Kaneko S
Psychopharmacology (Berl); 2002 Jun; 162(1):50-4. PubMed ID: 12107617
[TBL] [Abstract][Full Text] [Related]
15. Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.
Calarge CA; Miller del D
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):163-9. PubMed ID: 21486167
[TBL] [Abstract][Full Text] [Related]
16. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.
Yasui-Furukori N; Mihara K; Takahata T; Suzuki A; Nakagami T; De Vries R; Tateishi T; Kondo T; Kaneko S
Br J Clin Pharmacol; 2004 May; 57(5):569-75. PubMed ID: 15089809
[TBL] [Abstract][Full Text] [Related]
17. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone.
Gomeni R; Heidbreder C; Fudala PJ; Nasser AF
J Clin Pharmacol; 2013 Oct; 53(10):1010-9. PubMed ID: 23868656
[TBL] [Abstract][Full Text] [Related]
18. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients.
Lee BH; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):658-62. PubMed ID: 16466670
[TBL] [Abstract][Full Text] [Related]
19. QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.
Llerena A; Berecz R; Dorado P; de la Rubia A
J Psychopharmacol; 2004 Jun; 18(2):189-93. PubMed ID: 15260906
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study.
Youngster I; Zachor DA; Gabis LV; Bar-Chaim A; Benveniste-Levkovitz P; Britzi M; Soback S; Ziv-Baran T; Berkovitch M
Dev Med Child Neurol; 2014 Oct; 56(10):990-4. PubMed ID: 24828442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
